^
    Back
    Association details:
    Biomarker:EGFR-RAD51 fusion
    Cancer:Lung Adenocarcinoma
    Drug:Conmana (icotinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Oncologist
    Title:

    Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR-RAD51 Fusion

    Excerpt:
    A young patient with lung adenocarcinoma harboring a rare EGFR-RAD51 fusion who responded to icotinib with a PFS of longer than 15 months.
    DOI:
    10.1634/theoncologist.2018-0732